HOME >> MEDICINE >> NEWS
Treatment response to Aricept® (donepezil hydrochloride) not predicted by Apolipoprotein E4 genotype or gender

WASHINGTON, D.C. 11 July, 2000 -- Aricept® (donepezil hydrochloride) demonstrated beneficial effects on cognition and global function over the course of one year in a double-blind, placebo-controlled, multinational study in patients with mild to moderate Alzheimer's disease (AD). In this study, treatment response was not predicted by Apolipoprotein E4 (ApoE4) genotype and/or gender, according to data presented today at the World Alzheimer Congress in Washington D.C.

ApoE is a lipoprotein that carries cholesterol in the blood. The exact role the ApoE4 allele plays in the pathogenesis of AD or in the memory decline of cognitively impaired elderly is unclear presently. Furthermore, much of the evidence concerning a correlation between ApoE4 copy number and the pathological features of AD (e.g. neuronal plaque density and the appearance of neurofibrillary tangles) is contradictory. It has been suggested that patients carrying an ApoE4 allele may have a more severe cholinergic deficit than those who do not.

"The reports of associations between ApoE4 genotype, gender and response to cholinesterase inhibitor therapy in AD patients are conflicting. In this recently completed study, a secondary analysis showed that the treatment response to ARICEPT®, a cholinesterase inhibitor, was not predicted by ApoE4 genotype and/or gender in patients with mild to moderate AD," says Hilkka Soininen, M.D., Ph.D., University of Kuopio, Kuopio, Finland.

This one-year multinational, double-blind, placebo-controlled study enrolled 286 patients with mild to moderate AD from 28 sites in five Northern European countries (Denmark, Finland, Norway, Sweden and The Netherlands). Patients were randomized to receive either ARICEPT® (n=142; 5 mg/day for 28 days, and then 10 mg/day) or placebo (n=144) for one year. The mean age of the patients enrolled in the study was 72.5 (range: 49-88 years).

Outcomes measures included evaluation of global function (the Gottf
'"/>

Contact: Celeste Torello, Pfizer Inc.
212-733-6471
Porter Novelli
10-Jul-2000


Page: 1 2

Related medicine news :

1. Treatment of cardiac lesions without anaesthesic
2. Treatment guidelines for kids with bipolar disorder published
3. University of Washington joins new Autism Treatment Network to provide better medical services
4. Treatment for brain tumor does not always follow recommendations
5. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
6. Treatment of ductal carcinoma in situ varies widely in United States
7. Treatment options expand for patients with neuropathic pain
8. Treatment interruption shows no benefit in drug-resistant HIV infection
9. Peanut Allergy: Major Advances in Treatment and Education
10. Release of results of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
11. Treatment helped reduce dose of inhaled corticosteroids while maintaining asthma control

Post Your Comments:
(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve Health, ... leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting services ... Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, custom ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo ... Indianapolis, have chosen Center for Hospice Care (CHC) for physician Hospice and ... at CHC as part of fulfilling their requirements for obtaining national Board Certification ...
(Date:9/3/2015)... ... 2015 , ... DriButts, a non-profit organization dedicated to helping ... Group to manufacture a long-lasting reusable diaper for warm weather climates where there ... 600 DriButts Diapers to rural areas of Haiti during a trip scheduled for ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... care community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado ... 2016, and has been carefully designed to serve up to 80 people living ...
Breaking Medicine News(10 mins):Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2
(Date:9/3/2015)... 2015 Research and ... of the "Global Craniomaxillofacial (CMF) Devices Market ... The global craniomaxillofacial devices market to grow at ... report covers the present and future scenario of ... calculate the market size, we use revenues generated ...
(Date:9/3/2015)... , Sept. 3, 2015 HeartWare International, ... of less invasive, miniaturized circulatory support technologies that are ... that its President and Chief Executive Officer, Doug ... Wells Fargo Healthcare Conference at 8:50 a.m. ET on ... 9-10, 2015 at The Hyatt Regency, Boston ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ( ... "Investigation Report on China Olmesartan Market, 2010-2019" report ... medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd ... olmesartan medoxomil was approved by FDA to enter the ... best- selling drug in the world after it succeeded ...
Breaking Medicine Technology:Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2China Olmesartan Investigation Market Report 2010-2019 2
Cached News: